Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.61 |
| ▸ | TSHR | P16473 | 3/20 | 0.61 |
| ▸ | VCAM1 | P19320 | 2/20 | 0.56 |
| ▸ | LMNA | P02545 | 3/20 | 0.55 |
| ▸ | GAA | P10253 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 3/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7335509 | 0.90 | ALDH1A1 (0.72) | ALDH1A1TSHRVCAM1LMNAGAA | |
| SCHEMBL11819840 | 0.90 | VCAM1 (0.62) | ALDH1A1TSHRVCAM1LMNAGAA | |
| SCHEMBL11818879 | 0.90 | VCAM1 (0.62) | ALDH1A1TSHRVCAM1LMNAGAA | |
| SCHEMBL11826011 | 0.90 | VCAM1 (0.62) | ALDH1A1TSHRVCAM1LMNAGAA | |
| SCHEMBL11822366 | 0.90 | VCAM1 (0.62) | ALDH1A1TSHRVCAM1LMNAGAA | |
| SCHEMBL11169188 | 0.84 | ALDH1A1 (0.55) | ALDH1A1TSHRLMNAGAAKDM4E | |
| SCHEMBL11203128 | 0.83 | ALDH1A1 (0.60) | ALDH1A1TSHRLMNAGAAKDM4E | |
| SCHEMBL4715259 | 0.80 | ALDH1A1 (0.56) | ALDH1A1TSHRVCAM1LMNAGAA | |
| SCHEMBL11175627 | 0.78 | SMN1; SMN2 (0.51) | ALDH1A1VCAM1LMNAKDM4EMAPT | |
| SCHEMBL11177193 | 0.78 | VCAM1 (0.49) | ALDH1A1TSHRVCAM1LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1615904-B1 | SUBSTITUTED BENZOSULPHONAMIDES AS POTENTIATORS OF GLUTAMATE RECEPTORS | ASTRAZENECA AB (SE) | 2008-02-27 | — | — | EP | disclosed |
| US-20070021606-A1 | Therapeutic compounds | ASTRAZENECA AB (SE) | 2007-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021606-A1 | Therapeutic compounds | GRIN1, GRIN3A, GRM2 | ALDH1A1 1721/4885TSHR 685/4885VCAM1 1527/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.